Icagen/McNeil’s ICA-17043 Is Lead Candidate To Be Second Sickle Cell Drug On Market
This article was originally published in The Pink Sheet Daily
Executive Summary
The compound is poised to begin Phase III; J&J subsidiary McNeil entered a U.S. co-development and commercialization partnership with innovator Icagen for the oral once-daily chronic treatment in June. The orphan drug has fast-track status at FDA.
You may also be interested in...
J&J Terminates Icagen Deal For Senicapoc
Icagen says it will decide whether to continue development of the drug in sickle cell anemia by this fall.
J&J Terminates Icagen Deal For Senicapoc
Icagen says it will decide whether to continue development of the drug in sickle cell anemia by this fall.
Icagen/J&J Sickle Cell Disease Treatment Hits Phase III Snag
An independent data monitoring committee recommends Phase III enrollment continue for ICA-17043, but only for patients on concurrent hydroxyurea therapy.